McDonald F, Miles D
Department of Oncology, Guy's and St Thomas' Hospital, London, UK.
Int J Clin Pract. 2003 Jul-Aug;57(6):530-4.
Docetaxel (Taxotere) and capecitabine (Xeloda) demonstrate synergy in pre-clinical studies and both show high single-agent efficacy in metastatic breast cancer patients previously treated with an anthracycline. The two drugs used in combination in a similar group of patients have been evaluated in a randomised phase III trial comparing this combination with single-agent docetaxel. The results of this study indicate the combination arm to be favourable with significantly superior median time to disease progression (6.1 vs 4.2 months, hazard ratio 0.652, p=0.0001), objective response rate and overall survival without a significant increase in the overall incidence of treatment related adverse effects. This combination of docetaxel and capecitabine provides improved survival prospects for patients with metastatic breast cancer. Ongoing studies will provide further data to optimise the scheduling and use of this combination in the future.
多西他赛（泰索帝）和卡培他滨（希罗达）在临床前研究中显示出协同作用，并且在先前接受过蒽环类药物治疗的转移性乳腺癌患者中，二者单药治疗均显示出较高疗效。在一组相似患者中联合使用这两种药物，已在一项随机III期试验中进行了评估，该试验将此联合方案与多西他赛单药治疗进行了比较。这项研究结果表明联合治疗组具有优势，疾病进展的中位时间显著更长（6.1个月对4.2个月，风险比0.652，p = 0.0001），客观缓解率和总生存期更高，且治疗相关不良反应的总体发生率没有显著增加。多西他赛与卡培他滨的这种联合方案为转移性乳腺癌患者提供了更好的生存前景。正在进行的研究将提供进一步数据，以便在未来优化该联合方案的给药方案和使用方法。
